Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612105 · ClinicalTrials.gov registry record · Phase 2
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT00612105 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 187 participants.
The verdict
NCT00612105, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of retigabine vs. placebo in reducing pain associated with post-herpetic neuralgia.
Interventions
- DRUG Placebo
- DRUG Retigabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612105
The ClinicalTrials.gov registry entry for NCT00612105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00612105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612105 about?
NCT00612105 is a clinical study titled "Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)". The purpose of the study is to evaluate the efficacy of retigabine vs. placebo in reducing pain associated with post-herpetic neuralgia.
What is the current status of trial NCT00612105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2007-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00612105?
The interventions under investigation include: Placebo (DRUG), Retigabine (DRUG).
Who is sponsoring clinical trial NCT00612105?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.